Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 580 | 84 | 493 |
| Samples | 212 | 42 | 169 |
| Peptides | 165 | 29 | 140 |
Function
CCNE1 · Cyclin E1
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK2, whose activity is required for cell cycle G1/S transition. This protein accumulates at the G1-S phase boundary and is degraded as cells progress through S phase. Overexpression of this gene has been observed in many tumors, which results in chromosome instability, and thus may contribute to tumorigenesis. This protein was found to associate with, and be involved in, the phosphorylation of NPAT protein (nuclear protein mapped to the ATM locus), which participates in cell-cycle regulated histone gene expression and plays a critical role in promoting cell-cycle progression in the absence of pRB. [provided by RefSeq, Apr 2016].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 156 amino-acid changes on canonical ENST00000262643 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCNE1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCNE1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 3/98 3% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 14/612 2% |
| Melanoma | 1/210 0% | 23/1899 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Neuroendocrine Tumour | 7/154 5% | 0/577 0% |
| Non-Small Cell Lung Carcinoma | 9/304 3% | 6/1390 0% |
| Gastric Carcinoma | 0/74 0% | 15/1809 1% |
| Bladder Carcinoma | 3/58 5% | 4/956 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Other Solid Cancers | 1/94 1% | 9/1515 1% |
| Colorectal Carcinoma | 2/143 1% | 19/3239 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 6/1592 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Breast Carcinoma | 2/144 1% | 6/3264 0% |
| Kidney Carcinoma | 1/85 1% | 2/1862 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 2/2640 0% |
| Neuroblastoma | 1/87 1% | 0/1331 0% |
Mutation Distribution
Where CCNE1 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCNE1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 580 mutations in CCNE1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|